Fairfax Financial Holdings Limited TORONTO, May 15, 2025 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that it has priced a private offering of US$500,000,000 of senior notes due 2035 (the “2035 Notes”) at an issue price of 99.632% and US$400,000,000 of senior notes due 2055 (the “2055 Notes” and,
VANCOUVER, BC, Aug. 22, 2024 /PRNewswire/ – Wheaton Precious Metals™ Corp. (“Wheaton” or the “Company”) is pleased to announce that it will host an Investor Day webcast on Tuesday, September 24, 2024, starting at 9:00am Eastern Time. Speakers will include Randy Smallwood, President and Chief Executive Officer, as well as the Wheaton Executive team. In
A-Mark Precious Metals (NASDAQ: AMRK) has scheduled its fiscal fourth quarter and full year 2024 earnings call for Thursday, August 29, at 4:30 p.m. ET. The company, a leading integrated precious metals platform, will release its financial results for the period ended June 30, 2024, prior to the call. Management
Jaguar Health (NASDAQ:JAGX) announced that Hong Kong’s Intellectual Property Department has issued a new patent to Napo Pharmaceuticals, a Jaguar family company, for methods of treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal using crofelemer. This patent strengthens Jaguar’s IP
Andean Precious Metals Corp. (TSXV: APM) (OTCQX: ANPMF) held its Annual General Meeting of Shareholders on August 15, 2024. The meeting saw a strong shareholder turnout, with 88.37% of the company’s total issued and outstanding shares represented. Shareholders approved all management resolutions, including: Fixing the number of directors at seven
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications
EDINBURGH, Scotland, Aug. 28, 2024 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has received a patent grant from European Patent Office (EPO) covering the use of modified gamma delta